Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Melanoma 69Carcinoma, Non-Small-Cell Lung 41Carcinoma, Renal Cell 38Neoplasm Metastasis 22Carcinoma, Hepatocellular 15Neoplasms 14Colorectal Neoplasms 13Brain Neoplasms 13Skin Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Pancreatic Neoplasms 10Lung Neoplasms 10Kidney Neoplasms 10Uveal Melanoma 9Ovarian Neoplasms 9Urinary Bladder Neoplasms 8Sarcoma 8Prostatic Neoplasms 8Carcinoma, Transitional Cell 8Mesothelioma 7Glioblastoma 7Clear-cell metastatic renal cell carcinoma 7Carcinoma, Merkel Cell 7Recurrence 6Myelodysplastic Syndromes 6Colonic Neoplasms 6Triple Negative Breast Neoplasms 5Small Cell Lung Carcinoma 5Multiple Myeloma 5Mesothelioma, Malignant 5

Interventions

lutetium Lu 177 dotatate 6Octreotide 3pasireotide 2lanreotide 2gallium Ga 68 dotatate 2copper dotatate CU-64 2amino-acid, glucose, and electrolyte solution 2Magnetic Resonance Spectroscopy 2Lutetium-177 2Lutetium 2Ga(III)-DOTATOC 2Everolimus 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2zimberelimab 1irinotecan sucrosofate 1abemaciclib 1X-Rays 1Temozolomide 1Sunitinib 1Receptor-Like Protein Tyrosine Phosphatases, Class 2 1Radiosurgery 1PM 01183 1Oxaliplatin 1Nivolumab 1Leucovorin 1Irinotecan 1Ipilimumab 1Folfox protocol 1Fluorouracil 1E-7386 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastro-enteropancreatic neuroendocrine tumor × Ipilimumab × 1 year × Clear all
NCT05262556 2025-08-07

NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas

Case Comprehensive Cancer Center

Phase 1 Active not recruiting
15 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡